Question 1

Are Wegovy and Ozempic the same drug?

Accepted Answer

Chemically, yes — both are semaglutide. They are sold under different names for different approved uses, and usually at different doses and different prices. That is a labeling and commercial distinction, not a pharmacological one, which is why a prescription for one is not automatically interchangeable with the other at the pharmacy counter.

Question 2

Is Wegovy or Ozempic cheaper?

Accepted Answer

On the manufacturers' own cash pricing: Wegovy at $349 first 2 mo / $499 maintenance via NovoCare, Ozempic at No manufacturer cash-pay program; savings card commercial-T2D only. ⚠ That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

Question 3

Does either one have better cardiovascular evidence?

Accepted Answer

Neither has a clear edge. Wegovy: MACE −20% in obesity without diabetes (SELECT, 2023). Ozempic: MACE −26% in T2D + high CV risk (SUSTAIN-6, 2016). This matters more than it first appears — a drug with a completed outcomes trial has evidence about events that matter, not only about weight, and that is often what decides coverage.

Question 4

What does a compounded version of each actually cost?

Accepted Answer

Across the 556 sellers in this register, the cheapest standing monthly cash prices we hold are semaglutide from $79 a month and semaglutide from $79 a month. ⛔ A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Question 5

Can I switch from Wegovy to Ozempic?

Accepted Answer

People move between them regularly, since it is the same molecule — but the dose ladders differ, so a prescriber has to map where you land rather than matching the number. Do not assume your current dose transfers.

Question 6

Which one should I ask for?

Accepted Answer

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

Field	Wegovy	Ozempic
Active ingredient	Semaglutide	Semaglutide
FDA-labeled indication	Chronic weight management; CV risk reduction in obesity (Mar 2024)	Type 2 diabetes; CV risk reduction in T2D + established CVD
Max labeled dose	2.4 mg once weekly	2.0 mg once weekly
Pivotal weight-loss trial	−14.9% TBWL / 68 wk (STEP-1, 2.4 mg)	−6.2% TBWL / 68 wk (STEP-2, 1.0 mg in T2D)
Mechanism	GLP-1 receptor agonist	GLP-1 receptor agonist
Cardiovascular outcome trial	MACE −20% in obesity without diabetes (SELECT, 2023)	MACE −26% in T2D + high CV risk (SUSTAIN-6, 2016)
Cash price (manufacturer direct)	$349 first 2 mo / $499 maintenance via NovoCare	No manufacturer cash-pay program; savings card commercial-T2D only
Commercial insurance PA criteria	BMI ≥30 (or ≥27 + comorbidity); obesity benefit (often excluded)	A1c ≥6.5% + metformin trial; T2D benefit (broadly covered)

Wegovy vs Ozempic: The Same Drug at Two Doses

The verdict

Side-by-side comparison

What each one costs in the compounded market

Frequently asked questions